Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE CHOICE OF DRUG FROM THE STANDPOINT OF EVIDENCE-BASED MEDICINE: CASE STUDY OF BETA-BLOCKERS

https://doi.org/10.20996/1819-6446-2010-6-6-876-881

Full Text:

Abstract

Basic principles of beta-blockers choice strategy are presented. Attention is focused on the facts concerning the evidence base for effects of various beta-blockers on the outcomes of cardiovascular diseases. Beta-blocker indications and safety of their long-term use are considered from this point of view. Convincing data about beta-blocker impact on the prognosis of cardiovascular disease should be the reason for any beta-blocker choice, as well as choice of their doses which were tested in large randomized trials.

About the Authors

S. Yu. Martsevich
State Research Center for Preventive Medicine, I.M. Setchenov First Moscow State Medical University
Russian Federation

Petroverigsky per. 10, Moscow, 101990 

Trubetskaya ul. 8-2, Moscow, 119991 



N. P. Kutishenko
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


Yu. V. Lukina
State Research Center for Preventive Medicine, I.M. Setchenov First Moscow State Medical University
Russian Federation

Petroverigsky per. 10, Moscow, 101990 

Trubetskaya ul. 8-2, Moscow, 119991 



References

1. EMEA (The European Agency for the Evaluation of Medicinal Products). Bioequivalence Guidelines/Regulations. Available on: http://www.gcphelpdesk.com/index.php/bioequivalence-guidelinesregulations.

2. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. WHO Technical Report Series, No. 937, 2006. Available on: http://apps.who.int/prequal/info_general/documents/TRS937/WHO_TRS_937__annex7_eng.pdf.

3. Poole-Wilson P.A., Swedberg K., Cleland J.G. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heartfailure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362(9377):7–13.

4. Drug facts and comparisons. Philadelphia: Lippincott Williams & Wilkins / Springhouse; 2009.

5. ESC GuidelinesDesk Reference2010:Compendium ofAbridged ESC Guidelines2010.1st Edition. Springer Healthcare Ltd.; 2010. p.336.

6. Olsson G., Tuomilehto J., Berglund G. et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991;4(2 Pt 1): 151-8.

7. Lever A.F., Brennan P.J. MRC working party. MRC trial of treatment in elderly hypertensives. Clin Exp Hypertens 1993;15(6):941-2.

8. Wilhelmsen L., Berglund G., Elmfeldt D. et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5(5):561-72.

9. Dahlöf B., Lindholm L.H., Hansson L. et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338(8778):1281-5.

10. Chen Z.M., Pan H.C., Chen Y.P. et al. Commit (ClOpidogrel and Metoprolol in Miocardial Infarction Trial) collaborative group. Early intravenous than oral metoprolol in 45582 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366(9497):1622-32.

11. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357(9266):1385–90.

12. Packer M., Bristow M.R., Cohn J.N. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334(21): 1349 – 55.

13. Hjalmarson Å., Goldstein S., Fagerberg B. et al. mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized International Trial in congestive heart failure (MERIT-HF). JAMA 2000;283(10):1295–302.

14. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353(9146):9-13.

15. Flather M.D., Shibata M.C., Coats A.J.S. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3): 215–225.

16. Packer M., Fowler M., Rouleau J. COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival Trial). A multicenter randomized double-blind, placebo-controlled study to determine the effect of carvedilol on mortality in severe congestive heart failure (absract). Cardiovasc Drugs Ther 1999;13(1):24.

17. Bakris G.L., Fonseca V., Katholi R.E. et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. A Randomized Controlled Trial. JAMA 2004; 292(18): 2227—2236.

18. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317(7160):713- 20.

19. Helfand M., Peterson K., Christensen V. et al. Drug Class Review. Beta Adrenergic Blockers. Final Report, update 4. 2009 by Oregon Health & Science University Portland, Oregon. Available on: http://derp.ohsu.edu/final/BB_Final_Report_Update%204_09_JUL.pdf.

20. Metra M., Guibbini R., Nodari S. et al. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102(5): 546-551.

21. Bangalore S., Parkar S., Grossman E., Messerli F.N. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of the new-onset diabetes mellitus. Am J Cardiol 2007; 100(8): 1254-1262.


For citation:


Martsevich S.Yu., Kutishenko N.P., Lukina Yu.V. THE CHOICE OF DRUG FROM THE STANDPOINT OF EVIDENCE-BASED MEDICINE: CASE STUDY OF BETA-BLOCKERS. Rational Pharmacotherapy in Cardiology. 2010;6(6):876-881. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-6-876-881

Views: 369


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)